Biocon Biologics is focused on improving cash flows and increasing market shares of its biosimilar products, particularly in the US and Europe. The company is dealing with rising pricing pressure and delays in key approvals. The integration of Viatris' biosimilar business, acquired for $3.34 billion, has been completed in 120 countries, one year ahead of schedule. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
